These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 17561792)

  • 1. Benefits of complementary therapy with insulin aspart versus human regular insulin in persons with type 2 diabetes mellitus.
    Chlup R; Zapletalová J; Seckar P; Malá E; Doubravová B; Táncosová S; Chlupová L; Pukowietz L; Zatloukal P
    Diabetes Technol Ther; 2007 Jun; 9(3):223-31. PubMed ID: 17561792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benefits of insulin aspart vs phosphate-buffered human regular insulin in persons with type 1 Diabetes treated by means of an insulin pump.
    Chlup R; Zapletalová J; Seckar P; Chlupová L; Táncosová S; Reznícková M
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2004 Jul; 148(1):27-32. PubMed ID: 15523542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of insulin aspart vs. regular human insulin with or without insulin detemir concerning adipozytokines and metabolic effects in patients with type 2 diabetes mellitus.
    Herrmann BL; Kasser C; Keuthage W; Huptas M; Dette H; Klute A
    Exp Clin Endocrinol Diabetes; 2013 Apr; 121(4):210-3. PubMed ID: 23512415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A direct efficacy and safety comparison of insulin aspart, human soluble insulin, and human premix insulin (70/30) in patients with type 2 diabetes.
    Bretzel RG; Arnolds S; Medding J; Linn T
    Diabetes Care; 2004 May; 27(5):1023-7. PubMed ID: 15111514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved postprandial glycaemic control with insulin Aspart in type 2 diabetic patients treated with insulin.
    Rosenfalck AM; Thorsby P; Kjems L; Birkeland K; Dejgaard A; Hanssen KF; Madsbad S
    Acta Diabetol; 2000 Mar; 37(1):41-6. PubMed ID: 10928235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.
    Ushakova O; Sokolovskaya V; Morozova A; Valeeva F; Zanozina O; Sazonova O; Zhadanova E; Starceva M; Kazakova E; Saifullina M; Shapiro I; Tarasov A; Al-Tayar B; Starkova N
    Clin Ther; 2007 Nov; 29(11):2374-84. PubMed ID: 18158078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes.
    Hermansen K; Fontaine P; Kukolja KK; Peterkova V; Leth G; Gall MA
    Diabetologia; 2004 Apr; 47(4):622-9. PubMed ID: 15298338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin aspart vs. human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial.
    Home PD; Lindholm A; Riis A;
    Diabet Med; 2000 Nov; 17(11):762-70. PubMed ID: 11131100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of biphasic insulin aspart in patients with type 2 diabetes.
    Halimi S; Raskin P; Liebl A; Kawamori R; Fulcher G; Yan G
    Clin Ther; 2005; 27 Suppl B():S57-74. PubMed ID: 16519038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized trial comparing continuous subcutaneous insulin infusion of insulin aspart versus insulin lispro in children and adolescents with type 1 diabetes.
    Weinzimer SA; Ternand C; Howard C; Chang CT; Becker DJ; Laffel LM;
    Diabetes Care; 2008 Feb; 31(2):210-5. PubMed ID: 17989308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin aspart: a review of its use in the management of type 1 and 2 diabetes mellitus.
    Chapman TM; Noble S; Goa KL
    Drugs; 2002; 62(13):1945-81. PubMed ID: 12215068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spotlight on insulin aspart in type 1 and 2 diabetes mellitus.
    Chapman TM; Noble S; Goa KL
    Treat Endocrinol; 2003; 2(1):71-6. PubMed ID: 15871555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-acting insulin analogues versus regular human insulin for adult, non-pregnant persons with type 2 diabetes mellitus.
    Fullerton B; Siebenhofer A; Jeitler K; Horvath K; Semlitsch T; Berghold A; Gerlach FM
    Cochrane Database Syst Rev; 2018 Dec; 12(12):CD013228. PubMed ID: 30556900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intensifying insulin regimen after basal insulin optimization in adults with type 2 diabetes: a 24-week, randomized, open-label trial comparing insulin glargine plus insulin glulisine with biphasic insulin aspart (LanScape).
    Vora J; Cohen N; Evans M; Hockey A; Speight J; Whately-Smith C
    Diabetes Obes Metab; 2015 Dec; 17(12):1133-41. PubMed ID: 26085028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential lipid profile and hormonal response in type 2 diabetes by exogenous insulin aspart versus the insulin secretagogue repaglinide, at the same glycemic control.
    Chisalita SI; Lindström T; Eson Jennersjö P; Paulsson JF; Westermark GT; Olsson AG; Arnqvist HJ
    Acta Diabetol; 2009 Mar; 46(1):35-42. PubMed ID: 18777156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Twice daily biphasic insulin aspart improves postprandial glycaemic control more effectively than twice daily NPH insulin, with low risk of hypoglycaemia, in patients with type 2 diabetes.
    Christiansen JS; Vaz JA; Metelko Z; Bogoev M; Dedov I
    Diabetes Obes Metab; 2003 Nov; 5(6):446-54. PubMed ID: 14617231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The switch from sulfonylurea to preprandial short- acting insulin analog substitution has an immediate and comprehensive beta-cell protective effect in patients with type 2 diabetes mellitus.
    Pfützner A; Lorra B; Abdollahnia MR; Kann PH; Mathieu D; Pehnert C; Oligschleger C; Kaiser M; Forst T
    Diabetes Technol Ther; 2006 Jun; 8(3):375-84. PubMed ID: 16800759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biphasic insulin aspart 30 in the treatment of elderly patients with type 2 diabetes: a subgroup analysis of the PRESENT Korea NovoMixstudy.
    Jang HC; Lee SR; Vaz JA
    Diabetes Obes Metab; 2009 Jan; 11(1):20-6. PubMed ID: 18479469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The combined effect of triple therapy with rosiglitazone, metformin, and insulin aspart in type 2 diabetic patients.
    Poulsen MK; Henriksen JE; Hother-Nielsen O; Beck-Nielsen H
    Diabetes Care; 2003 Dec; 26(12):3273-9. PubMed ID: 14633813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addition of biphasic insulin aspart 30 to rosiglitazone in type 2 diabetes mellitus that is poorly controlled with glibenclamide monotherapy.
    Raz I; Mouritzen U; Vaz J; Hershkovitz T; Wainstein J; Harman-Boehm I
    Clin Ther; 2003 Dec; 25(12):3109-23. PubMed ID: 14749149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.